Crispin T. Hiley

The Francis Crick Institute — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

42h-index17.7kcitations203works5.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(52), Lung Cancer Diagnosis and Treatment(44), Lung Cancer Treatments and Mutations(38), Cancer Immunotherapy and Biomarkers(37), Immunotherapy and Immune Responses(34)

Publications187 total

298 The Posthumous Evaluation of Advanced Cancer Environment (PEACE) Study
Lung Cancer·2026
Retracted - Antibodies against endogenous retroviruses promote lung cancer immunotherapy.
The Francis Crick Institute·2026Open Access
Retracted - Antibodies against endogenous retroviruses promote lung cancer immunotherapy.
The Francis Crick Institute·2026Open Access
Investigating the Immune Effects of Radiotherapy in Non-Small Cell Lung Cancer—Results of the PD-RAD Study
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics·2026
Somatic evolution following cancer treatment in normal tissue
Nature·2025Open Access
Loss of IDH1 and IDH2 mutations during the evolution of metastatic chondrosarcoma
Genome biology·2025Open Access
COMPARISON OF PBT AND VMAT FOR RADICAL HEMOTHORACIC RADIOTHERAPY FOR MALIGNANT PLEURAL MESOTHELIOMA
International Journal of Particle Therapy·2025Open Access
The concept of virtual clinical trials: A game changer in radiation oncology research?
Radiotherapy and Oncology·2025Open Access
P3.09.02 Stereotactic Mr-Guided Adaptive Radiotherapy (SMART) for Ultracentral Non-Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology·2025
P2.08.19 Proton Beam Therapy for Lung Cancer in Patients With Interstitial Lung Disease: Initial Experience From the United Kingdom
Journal of Thoracic Oncology·2025
Safety and Efficacy of Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) for Ultracentral Metastases in Non-Small Cell Lung Cancer
Advances in Radiation Oncology·2025Open Access
Delphi Consensus on Managing Non-Small Cell Lung Cancer (NSCLC) in Patients with Coexisting Interstitial Lung Disease
International Journal of Radiation Oncology*Biology*Physics·2025· 1 citedOpen Access
DNA methylation cooperates with genomic alterations during non-small cell lung cancer evolution
Nature Genetics·2025· 4 citedOpen Access
1909P Radiological and molecular patterns of metastatic growth in lung cancer within TRACERx
Annals of Oncology·2025
Subclonal immune evasion in non-small cell lung cancer
Cancer Cell·2025· 12 citedOpen Access
2471 Conventional Radiotherapy and Thoracic SABR for Synchronous Oligometastatic NSCLC: Acute Toxicity Findings from the SARON Thoracic Safety Sub-Study
Radiotherapy and Oncology·2025
Abstract 1207: The evolution of immunity and immune evasion from early- to end-stage lung cancer
Cancer Research·2025
Abstract 4560: Use of ctDNA fragmentomics as a predictive biomarker in locally advanced non-small cell lung cancer
Cancer Research·2025
Abstract 6421: Tracking the evolution of non-small-cell lung cancer: Completion of the TRACERx longitudinal cohort
Cancer Research·2025
Clonal driver neoantigen loss under EGFR TKI and immune selection pressures
Nature·2025· 14 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

Charles Swanton(25), Selvaraju Veeriah(24), Nicholas McGranahan(23), Sergio A. Quezada(20), Sophia Ward(20), Mariam Jamal‐Hanjani(19), Nicolai J. Birkbak(19), David A. Moore(19), Maise Al Bakir(19), Rachel Rosenthal(18), Gareth A. Wilson(17), Teresa Marafioti(15), Peter Van Loo(15), Javier Herrero(14), Thomas B.K. Watkins(13), Kevin Litchfield(13), Andrew Rowan(12), Martin Förster(12), Allan Hackshaw(12), Mary Falzon(11)